Ceribell Secures $50 Million Funding to Revolutionize Seizure Management with AI-Powered EEG Diagnostic System

Ceribell, Inc., the pioneering medical technology company behind the first AI-powered point-of-care EEG diagnostic system, has achieved a significant milestone in its mission to revolutionize seizure management in acute care settings by successfully raising an impressive $500 million in funding. This infusion of capital comes at a crucial time as Ceribell aims to further establish the Ceribell System as the gold standard for EEG diagnostics in hospitals. The Ceribell System, a game-changer for clinicians, combines highly portable, rapidly deployable hardware with sophisticated AI algorithms to provide swift, accurate diagnoses and ongoing monitoring for patients experiencing neurological emergencies. Already FDA 510(k) cleared for identifying suspected seizure activity and recognized for its unique capabilities with two Breakthrough Device Designations, the system is currently making a significant impact in intensive care units and emergency rooms across the U.S. The recent advancements, including the Clarity™ AI algorithm, further underscore Ceribell's commitment to innovation, as it became the first device to receive 510(k) clearance for diagnosing electrographic status epilepticus. The funding raised will not only support the scaling up of production and distribution but will also facilitate ongoing research and development initiatives, ensuring that Ceribell continues to meet the unmet needs of patients and clinicians alike in their fight against serious neurological conditions. With this capital injection, Ceribell is poised to save more lives by enhancing the standard of care in acute seizure management.